Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock

NEXT STORY
Roche opens access to pathology imaging tools to improve patient care
PREV STORY
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer

MacroGenics licenses MGD015 to Janssen$75 Million upfront license fee paid to MacroGenicsMacroGenics may elect ...

author_avatar
NASDAQ Market News

ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016

BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that ...

author_avatar
NASDAQ Market News

Editas Medicine Expands Senior Management Team

-- Appoints Gerald Cox, M.D., Ph.D., as Chief Medical Officer -- -- Kenneth LeClair, ...

author_avatar
NASDAQ Market News